Company updates
Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma
Jupiter, FL, [October 22, 2025] — Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class...
Pipeline
Myosin Therapeutics is built around a platform for discovery of novel small molecule modulators for the understudied, but biologically important superfamily of molecular nanomotors
Discovery / Preclinical
Translation
Phase 2
Phase 1 (Safety and POC)
Preclinical Safety Studies & IND filing
Lead Optimization
Hit-to-Lead
Screen
Indication
Glioblastoma
Pancreatic ductal adenocarcinoma
Acute Myeloid Leukemia
Meth Use Disorder
Cocaine Use Disorder
Discovery / Preclinical
Translation
Indication
Screen
Hit-to-Lead
Lead Optimization
Preclinical Safety Studies & IND filing
Phase 1 (Safety and POC)
Phase 2
Glioblastoma
Pancreatic ductal adenocarcinoma
Acute Myeloid Leukemia
Meth Use Disorder
Cocaine Use Disorder
News
The latest news in the field of our research and development financing.
